Full View

Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome

CM Legendre, C Licht, P Muus… - … England Journal of …, 2013 - Mass Medical Soc
Background Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
被引用次数：1683 相关文章

[引用][C] Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

CM Legendre, C Licht, P Muus, LA Greenbaum… - 2013 - repository.ubn.ru.nl
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

CM Legendre, C Licht, P Muus… - The New England …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome

CM Legendre, C Licht, P Muus… - New England Journal …, 2013 - lup.lub.lu.se
Background Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome

CM Legendre, C Licht, P Muus… - … England Journal of …, 2013 - portal.research.lu.se
Background Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …

[引用][C] Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

CM Legendre, C Licht, P Muus… - New England Journal …, 2013 - eprints.ncl.ac.uk
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome - ePrints
- Newcastle University Newcastle University Toggle Main Menu Toggle Search Home Browse …

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

CM Legendre, C Licht, P Muus… - The New England …, 2013 - europepmc.org
Background Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
[PDF] uzh.ch

[PDF][PDF] Eculizumab in Atypical Hemolytic–Uremic Syndrome

Y Wang, SC Johnston, Y Wang - N Engl J Med, 2013 - zora.uzh.ch
To the Editor: With regard to the article by Legendre et al.(June 6 issue) 1: assessment of the
37 patients with atypical hemolytic–uremic syndrome is difficult, since the process of …

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

CM Legendre, C Licht, P Muus… - NEW ENGLAND …, 2013 - air.unimi.it
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
[PDF] researchgate.net

[PDF][PDF] Eculizumab in Atypical Hemolytic–Uremic Syndrome

Y Wang, SC Johnston, Y Wang - N Engl J Med, 2013 - researchgate.net
To the Editor: With regard to the article by Legendre et al.(June 6 issue) 1: assessment of the
37 patients with atypical hemolytic–uremic syndrome is difficult, since the process of …